{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:28Z","timestamp":1793177908051,"version":"4.5.0"},"reference-count":81,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a major driver. Clinically, TB presents as \u201clatent\u201d TB and active TB disease, and the treatment for each is different. TB drugs can display \u201cearly bactericidal activity (EBA)\u201d and \/ or \u201csterilizing activity\u201d (clearing persisters). Isoniazid is excellent at the former, and rifampin is excellent at the latter. Pyrazinamide and ethambutol complete the first\u2010line regimen for drug\u2010susceptible TB, each playing a specific role. Drug\u2010resistant TB is an increasing concern, being met, in part, with repurposed drugs (including moxifloxacin, levofloxacin, linezolid, clofazimine, and beta\u2010lactams) and new drugs (including bedaquiline, pretomanid, and delamanid). One challenge is to select drugs without overlapping adverse drug reaction profiles. QTc interval prolongation is one such concern, but to date, it has been manageable. Drug penetration into organism sanctuaries, such as the central nervous system, bone, and pulmonary TB cavities remain important challenges. The pharmacodynamics of most TB drugs can be described by the area under the curve (AUC) divided by the minimal inhibitory concentration (MIC). The hollow fiber infection model (HFIM) and various animal models (especially mouse and macaque) allow for sophisticated pharmacokinetic\/pharmacodynamic experiments. These experiments may hasten the selection of the most potent, shortest possible regimens to treat even extremely drug resistant TB. These findings can be translated to humans by optimizing drug exposure in each patient, using therapeutic drug monitoring and dose individualization.<\/jats:p>","DOI":"10.1002\/cpt.2261","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T04:13:01Z","timestamp":1618027981000},"page":"1455-1466","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["The Treatment of Tuberculosis"],"prefix":"10.1111","volume":"110","author":[{"given":"Charles A.","family":"Peloquin","sequence":"first","affiliation":[{"name":"College of Pharmacy and Emerging Pathogens Institute University of Florida Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraint R.","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Infection and Global Health University of Liverpool Liverpool UK"},{"name":"Institute of Translational Medicine University of Liverpool Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"e_1_2_15_1_1","unstructured":"Global Tuberculosis Report 2020.Geneva:World Health Organization;2020<https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131\u2010eng.pdf?ua=1>. Accessed November 3 2020."},{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2010.199505"},{"key":"e_1_2_15_3_1","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Namdar R."},{"key":"e_1_2_15_4_1","unstructured":"Treatment Action Group.Public Investment in Bedaquiline Up to Five\u2010Fold That of Johnson and Johnson<https:\/\/www.treatmentactiongroup.org\/statement\/public\u2010investment\u2010in\u2010bedaquiline\u2010up\u2010to\u2010five\u2010fold\u2010that\u2010of\u2010johnson\u2010johnson\/>. Accessed November 3 2020."},{"key":"e_1_2_15_5_1","unstructured":"Working Group on New TB Drugs.Clinical Pipeline<https:\/\/www.newtbdrugs.org\/pipeline\/clinical>. Accessed November 3 2020."},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.08.001"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.10.018"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.02.005"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"e_1_2_15_10_1","first-page":"935","article-title":"A controlled trial of community\u2010wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock G.W.","year":"1967","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_15_11_1","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"Comstock G.W.","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_15_12_1","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock G.W.","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1482"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0486"},{"issue":"10","key":"e_1_2_15_17_1","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox W.","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_15_18_1","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison D.A.","year":"2000","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_15_19_1","volume-title":"A clinician's guide to tuberculosis","author":"Iseman M.D.","year":"2000"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"e_1_2_15_22_1","unstructured":"WHO consolidated guidelines on drug\u2010resistant tuberculosis treatment.Geneva:World Health Organization<https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311389\/9789241550529\u2010eng.pdf?ua=1> (2019). Accessed November 3 2020"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"e_1_2_15_25_1","unstructured":"Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB XDR\u2010TB Pre\u2010 XDR\u2010TB or non\u2010responsive\/intolerant MDR\u2010TB (ZeNix)<https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03086486>. Accessed November 3 2020"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01741-15"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2018.04.008"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2019.08.001"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rppnen.2017.10.009"},{"key":"e_1_2_15_30_1","volume-title":"Anti\u2010tuberculosis Drugs","author":"Bartmann K.","year":"1988"},{"key":"e_1_2_15_31_1","volume-title":"Drug Susceptibility in the Chemotherapy of Mycobacterial Infections","author":"Heifets L.","year":"1991"},{"key":"e_1_2_15_32_1","unstructured":"Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents 2005 (and subsequent on\u2010line only updates).Pittsburgh;Esun Technologies LLC<http:\/\/www.antimicrobe.org>."},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781351249980"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1836158"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy026"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7786"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13345"},{"key":"e_1_2_15_40_1","unstructured":"CDC.Media statement: Landmark TB trial identifies shorter\u2010course treatment regimen. Oct. 22 2020<https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2020\/landmark\u2010tb\u2010trial\u2010media\u2010statement.html>."},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00127"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000570"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx506"},{"key":"e_1_2_15_44_1","unstructured":"Pretomanid Full Prescribing Information<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212862Orig1s000Lbl.pdf>. Accessed November 5 2020."},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00849-10"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701102"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.3.9807131"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14395"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00089808"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48289-9"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00379-15"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2333OC"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.120"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00764-2"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70264-5"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.07.002"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2011.04.239"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1737.191867"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2020.100151"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2003.08.016"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01389-08"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9894-2"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.09.033"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2704-6"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"e_1_2_15_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315817"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"e_1_2_15_68_1","article-title":"The role of therapeutic drug monitoring in mycobacterial infections","volume":"5","author":"Peloquin C.","year":"2016","journal-title":"Microbiol. Spectrum."},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv183"},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TBTB2\u20100034\u20102017"},{"key":"e_1_2_15_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.8b00985"},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01727-19"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-030920-011143"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105421"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.08.034"},{"key":"e_1_2_15_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00856-18"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01470-18"},{"key":"e_1_2_15_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01376-20"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02533-20"},{"key":"e_1_2_15_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02172-20"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01610-20"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T08:30:05Z","timestamp":1699345805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/cpt.2261"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2261","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"2020-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}